How Can the Multidisciplinary Team Optimize Patient Care?
Through a case involving recurrent scalp CSCC and cognitive impairment, faculty explore how recurrence risk, treatment feasibility, patient preferences, and caregiver involvement influence decisions about surgery, radiation, and adjuvant immunotherapy.
This is Part 3 of 4:
Part 1: When Is Surgery Alone No Longer Enough?
Part 2: How Do You Determine the Best Treatment Strategy?
Part 3: How Can the Multidisciplinary Team Optimize Patient Care?
Part 4: Practical Strategies for Multidisciplinary CSCC Care
Dr Stan Tolkachjov: Last case here, let's see. So how can the multidisciplinary team optimize patient care beyond the initial treatment decision?
Dr Kevin Emerick: So, this last case is an 80-year-old gentleman who presented with a left parietal scalp cutaneous squamous cell carcinoma. And like a lot of these folks, it was ulcerated, coming down. And as we tried to move it, it didn't move quite as well as we'd like it to. Initial biopsy showed poorly differentiated squamous cell carcinoma. This is a patient I think many of us see on a regular basis. In his 80s, as I mentioned, but also has AFib and is currently anticoagulated, but also has really significant dementia to the point that in doing a capacity assessment, does not have the capacity to make decisions, but does have a loving spouse who's actually great in terms of being able to comprehend and contribute to medical discussion. She was actually a retired nurse, which can be really helpful because she's also the healthcare proxy and ultimate decision maker.
And so, when we met this patient, we decided to go ahead and move forward with excision with complete margin assessment and ended up with a tumor that was 2.1 centimeters, poorly differentiated, did have multifocal greater than 0.1 PNI, and was deeply invasive down through the galea. So, beyond the fascial layer, even without measuring six millimeters, has multiple high-risk features. And so maybe I'll pause here and ask Stan, for you, for this, how would you approach this surgically? Is this a patient you'd approach surgically?
Dr Stan Tolkachjov: Absolutely. That's a really great point. So, the keys here, first of all, how significant is his dementia? Meaning, can he sit down for surgery while he's awake? Because that's what Mohs surgery is. We see this very commonly, of course, large scalp tumors that do have this PNI, and also have poor diff. A lot of times when they're first referred to us, as you mentioned, they're ulcerated, they may be fungating. And so, for those patients, interesting because you said the final pathology is 2.1. So, actually about Brigham and Women's, that would be one of the risk factors. He'd probably start with a smaller tumor than prior to doing the excision, right? But this is somebody that if they can sit down and be able to tolerate a surgery while awake, I would consider this a Mohs candidate, because the procedural part of Mohs surgery is very short. It's taking a layer, right? And then, of course, we have to process. That's the longest time, and that's a lot of work in pathology. But if we can then clear the patient, then we can then have the discussion what is the next step for that patient, whether it's radiation, imaging. And we may identify those factors, as you identified in your pathology as well, of poor differentiation and perineural invasion. Because that, and you mentioned it beautifully, that when you get to that galeal point, or you get to another tissue plane, if you will, that creates so many more risk factors and actually allows some of these tumors not just to follow the nerves, but potentially get into the galeal planes, which can make them much wider and create a larger radiation field as well. And do you remember with this patient, you did not have to do any kind of outer table removal, periosteal removal, just cutaneous surgery down to the galea or through the galea?
Dr Kevin Emerick: To the galea, yeah, left the periosteum.
So, this is somebody, as I think about him, that is at a high risk of local recurrence based on the presence of PNI. The other things don't bother me as much in terms of local recurrence, to be honest. But he's also at significant risk of regional recurrence based on multiple high-risk features. So how would you think about this patient for postoperative radiation therapy? High risk of local recurrence, high risk of regional recurrence, has significant dementia. Where does radiation fall for this patient for you?
Dr Mehran Yusuf: I think exactly like you mentioned, Stan, as well. It ends up really depending on what the patient looks like when you examine them, their family support and what their goals are, as well. Because exactly like you guys mentioned, we talk about recurrence. So, when does that happen? Half of them may happen by one year. Almost all of them happen by three years. So, if you have a patient who, because of other comorbidities, may have six months of life, those are often the patients where I'm like, it would be kind of wrong if I put you through six weeks of treatment in my clinic and you're recovering from these side effects for the majority of the remainder of your life.
When we talk about patients with dementia, oftentimes for radiation planning, it can be a scary process depending on the person's understanding of it. If they don't really know what's going on, it's in a dark room, they have a mask, they're immobilized. So, we try to assess that and their level of support as well. We take care of a lot of patients who, for whatever reason, don't have much family support, maybe in assisted living facilities, and they may not be able to deal with some of the aftercare that you really need to recover from the radiation side effects as well.
Radiation can be done a lot of different ways. So, you're exactly right, Kevin. This person we worry about, lymph nodes is a potential area where they could recur. The head and neck is so complicated, sometimes we'll pick the highest risk basins. We're now using sentinel node a little bit more to try to map out where they may go for individual tumors. But this is such a tough case for some of the underlying factors in terms of the dementia and then just the other health factors as well.
Dr Kevin Emerick: I'm going to go to the next slide. So, for those reasons, we did not feel like he was going to do very well with radiation therapy, in that moment. And there was a good chance that he was actually cured, right? Perhaps 75% chance, maybe even a little bit higher. And so, we set on a course of close clinical observation and monitoring.
Unfortunately, several months later, if we can go to our next slide, he did end up developing two subcutaneous nodules that were distinctly separate from the initial surgical site that very much fit with what felt like, clinically, an in-transit metastasis. And we did a biopsy that, again, confirmed squamous cell. Highlighting our previous conversation, that then prompted a systemic imaging workup to help guide our next steps. And it really showed that those were his only two sites of disease. And so, at that point, we had a multidisciplinary discussion to try to figure out what's the best way to help this gentleman.
Su, I'm wondering for you, in this moment, as detectable active disease, would you consider immunotherapy in this patient, in this moment?
Dr Sunandana Chandra: Yeah, that's a great question. Certainly, the person's age would not preclude him. Their comorbidities and cardiovascular disease, etc, would not preclude him. But I think what I would worry about is his capacity, A, to be able to give consent, informed consent, and B, for him to be able to really articulate if he's experiencing side effects because I'm really reliant on my patient reporting anything that seems out of the ordinary and symptoms that are persisting, etc, etc.
So, for someone who has significant dementia, I would worry that they may, first of all, not quite understand why they're getting a therapy and not truly be able to provide consent. But let's say they have a POA and they provide proxy consent, etc. I'm still worried that the person may not be able to really verbalize any discomfort that I might be causing them with this type of therapy. And, time and time again, we've seen that when we catch immune-related adverse effects early, they do better. Outcomes are better. We can shorten the course of steroids, we can hopefully, there can be a resolution of their immune-related AE, but in someone who may not be able to articulate it clearly and in a timely manner, I do worry that I'd be doing more harm than good.
Dr Stan Tolkachjov: I think you guys both brought up really good points of the human side of what we do. So, first of all, we've got to consider the dementia. And dementia, there's different kinds of dementia, right? Somebody may be combative or somebody that may overall be pleasant, right? And the levels of that. But also, when you look at their initial staging, right, that's a T2b with other multiple risk factors as well but has not gone into the bone yet. So, can that patient be radiated? Absolutely. That's a reason to get radiation. However, on the human perspective, you chose the discussion with his wife and his family that maybe for this particular patient, we need to defer radiation and consider maybe clear margins and go from there. And so, these are the decisions we come to every single day. And then after that point, if the patient did not get that radiation, would he be a candidate for immunotherapy? And I think that's the other question that we have to consider because once they are metastatic, or at least in-transit metastases, do we go back to more surgery? Do we go back to do more radiation? Obviously, at that point, it's not Mohs surgery at that point, right? But is the immunotherapy an option? And I think then you'll go back to that human aspect and see, can the patient tolerate it? And those are all really great points you all three have brought up in this particular case, because that rounds out a lot from not just the science that we know, the clinical trials that we've done, but also from the patients that we see every single day, and we face them and their family and make those multidisciplinary decisions, but also patient-centered decisions. Right? And so, that's a really good point.
Kevin, what other points about this case that you want to stress also?
Dr Kevin Emerick: So, because we were worried, but also recognizing this person in front of us who is likely to have a very symptomatic disease in the next few weeks to months, we still felt like we needed to think about cancer-directed therapies. We did discuss supportive care only, but despite his dementia, he's actually really healthy outside of his AFib. And so, we felt like we needed to at least consider with his wife, what would be a reasonable potential. And we looked back at our past experience. He actually did really well with previous surgery. And so, we ultimately decided to do more surgery for him.
Again, we did complete margin assessment surgery. In this case, because it was stuck to the periosteum, it wasn't going into the bone, but we went ahead and did an outer table craniectomy as well. Helped facilitate his reconstruction with a skin graft, as well. And not surprisingly, we found a poorly differentiated tumor with PNI, with LVI, really consistent with in-transit metastasis. And so, now we have a patient who we resected, was at high risk, proved he was high risk by coming back, developed disease. We've now removed his disease again. He's now, I would say, extremely high risk of having recurrent disease again. And so, we reconsidered whether or not something like radiation could be helpful for him. I'm wondering how you think about that? Does that experience change, for you, how you might think about postoperative radiation for him in this moment, and what kind of different radiation modalities might you consider for him?
Dr Mehran Yusuf: Absolutely. I definitely agree with you, Kevin. Up front, he had some high-risk features, which you guys identified, but you also really, I think, nicely brought up the majority of those patients are still cured with surgery. I think in this situation, the disease has biologically declared itself as being less amenable to that being like a curative modality on its own. And so, if somebody can get radiation, we definitely consider it. And we try to figure out ways to make it as palatable and tolerable and the best therapeutic ratio for a patient. So, what could that be? It definitely influences the volumes you pick. Oftentimes with in-transit lesions, you do target a bigger swath of dermal lymphatics, just being in an at-risk space. You might target the interconnection with the original primary site, margin around the flap, or the graft. Lymph nodes-wise, when we're doing elective nodal irradiation, sometimes we will use GEP in cases that we want to see if we can do anything to limit it. Maybe we'll pick the highest risk basin that's the least able to be salvaged without morbidity.
Modality-wise, I think here we really want to avoid brain radiation dose. So, whether it's using photons and other technology like protons, I think picking angles that skims the scalp without direct entrance is really, really important. Other things, anyone who's having neurocognitive changes, we want to make sure that we protect the ear, like the inner ear, the cochlea, because if you cause some level of deafness, I feel like that can sometimes accelerate the process of, you're already, you're not remembering things quite as well. If you can't hear as well, I want to avoid anything that does something like that. Shorter courses I think we're using a lot. So, based on the melanoma experience, we're sometimes doing five treatments and you can do that as few as one or two times a week, which can make this more affordable and accessible to people who are coming from further out.
Dr Stan Tolkachjov: I think a lot of us don't know, we refer for radiation, we know what some of the typical consequences are and how long that may take. But just to consider those things, that's where it takes an expert and somebody that really knows what they're doing. And I appreciate that conversation with a patient, rather than myself as a surgeon, who cannot have that same conversation, and choose that.
And the last thing, I know we're getting close to the time, but I want to also ask Kevin, where does sentinel lymph node biopsy for SCC, cutaneous SCC, fit into this case and other cases? Because I know we don't do it very often. But we do know that when they are done, a lot of times these mets are caught. Because when I do Mohs surgery, a lot of times I may clear the tumor. And if the patient has a metastasis of lymph nodes, that's likely because that tumor has already buttered off and gone off to the lymph node. And by local therapy, whether it's wide local excision or Mohs, would not have caught that. Where does SLNB fit?
Dr Kevin Emerick: I think the sentinel lymph node biopsy has the real potential to make a massive impact for these patients because surgery can truly cure them. Oftentimes, you're finding a single microscopic lymph node. I did some lymph node biopsy for many years, and I don't anymore. And the reality is, we cannot predict who is actually at risk. As much as we can talk about risk calculators, we can talk about BWH, we can talk about AJCC staging, they are so imperfect. I don't say that to be critical of any of those folks that put those things together. But that data is truly so unreliable, at this point to recommend a surgical procedure for this patient population, someone in their 80s with Alzheimer's, someone who's a transplant patient. I look forward to the day when we can really know who's truly at risk so we can do sentinel lymph node biopsy and help those patients.
I do wonder, just to go back to this patient again, Su, if this patient didn't have dementia. They are now in the uber high risk. I don't think “uber” was technically in the C-POST vocabulary, but they had a high-risk tumor that met the criteria beforehand. They recurred. They now have in-transit, and all of the histopathological features. We actually sent him for radiation, which he got. Would you now consider immunotherapy for him if we take away the dementia piece?
Dr Sunandana Chandra: You know, I think I would. I mean, certainly the person fits the high-risk characteristics that we think about when we are considering adjuvant immunotherapy.
Again, comorbidity-wise, performance status-wise, it doesn't seem like anything is really standing out that would put them at higher risk. But I do recognize that a person in their 80s might be significantly impacted, with respect to the quality of life, if I do cause a pretty significant immune-related adverse event. So, I would just want to have a very thorough, in-depth conversation as to the potential for these toxicities, but at the same time try to parse through the data in an understandable way so that they could hopefully understand why that could be potentially beneficial for them and their disease. So, in a nutshell, Kevin, I think I would recommend it, but it would have to require some thoughtful discussion.
©️ 2026 HMP Global. All Rights Reserved.
This is a non-CME activity. The views and opinions expressed by the presenter(s) do not necessarily reflect the views and opinions of The Dermatologist, HMP Global, or its employees and affiliates.


